{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:58:39Z","timestamp":1791298719798,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antibody\u2010drug conjugate (ADC) MORAb\u2010202, consisting of farletuzumab paired with a cathepsin B\u2013cleavable linker and eribulin, targets folate receptor alpha (FRA), which is frequently overexpressed in various tumor types. MORAb\u2010202 was highly cytotoxic to FRA\u2010positive cells in vitro, with limited off\u2010target killing of FRA\u2010negative cells. Furthermore, MORAb\u2010202 showed a clear in vitro bystander cytotoxic effect in coculture with FRA\u2010positive\/negative cells. In vivo antitumor efficacy studies of MORAb\u2010202 were conducted with a single administration of MORAb\u2010202 in triple\u2010negative breast cancer (TNBC) patient\u2013derived xenograft (PDx) models expressing low and high levels of FRA. MORAb\u2010202 exhibited durable efficacy proportional to tumor FRA expression. Toxicology studies (Q3Wx2) in nonhuman primates suggested that the major observed toxicity of MORAb\u2010202 is hematologic toxicity. Overall, these findings support the concept that MORAb\u2010202 represents a promising investigational ADC for the treatment of TNBC patients.<\/jats:p>","DOI":"10.1111\/cas.14898","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T16:45:42Z","timestamp":1616517942000},"page":"2467-2480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antibody\u2010drug conjugate MORAb\u2010202 exhibits long\u2010lasting antitumor efficacy in TNBC PDx models"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-6283","authenticated-orcid":false,"given":"Keiji","family":"Furuuchi","sequence":"first","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Rybinski","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fulmer","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Tsukuba Research Laboratory Eisai, Co. Ltd Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Drozdowski","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allis","family":"Soto","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Fernando","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrianne","family":"Wilson","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Milinichik","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Dula","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Tsukuba Research Laboratory Eisai, Co. Ltd Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"Albone","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Uenaka","sequence":"additional","affiliation":[{"name":"Epochal Precision Anti\u2010Cancer Therapeutics (EPAT) Eisai Inc Exton PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.03.007"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122209"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920915980"},{"key":"e_1_2_8_6_1","first-page":"1","article-title":"Farletuzumab (MORAb\u2010003) in platinum\u2010sensitive ovarian cancer patients experiencing a first relapse","volume":"03","author":"Armstrong D","year":"2010","journal-title":"Community Oncology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0700"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0345"},{"key":"e_1_2_8_10_1","first-page":"1611","article-title":"Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions","volume":"32","author":"Towle MJ","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12488"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.435"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2016-011"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1215"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0740-2"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0994-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111989"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.13"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29937"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.412"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014539183"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1757067"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01281-4"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw203"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6605"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.33"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13392"},{"key":"e_1_2_8_37_1","first-page":"401","article-title":"Mesenchymal\u2010epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer","volume":"38","author":"Kashiwagi S","year":"2018","journal-title":"Anticancer Res"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1443-5"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4925"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.12.008"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-396962-0.00010-0"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.122"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.519"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.05.018"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0309-OA"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2868-7"},{"key":"e_1_2_8_48_1","first-page":"6","article-title":"Preclinical evaluation of MORAb\u2010003, a humanized monoclonal antibody antagonizing folate receptor\u2010alpha","volume":"7","author":"Ebel W","year":"2007","journal-title":"Cancer Immun"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0180-8"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.01.014"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.14898","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T19:43:51Z","timestamp":1692560631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/cas.14898"],"URL":"https:\/\/doi.org\/10.1111\/cas.14898","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}